Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea

Oncology

Volumn 81, Issue SUPPL. 1, 2011, Pages 141-147

  Choi, Jong Young ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Radiation therapy

Indexed keywords

FIBROBLAST GROWTH FACTOR; PLACEBO; SORAFENIB; STEM CELL FACTOR; VASCULOTROPIN;

ADVANCED CANCER; ALGORITHM; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DRUG EFFICACY; HUMAN; KOREA; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER NECROSIS; LIVER TRANSPLANTATION; LONG TERM CARE; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARD; SURVIVAL RATE; TUMOR VOLUME;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MOLECULAR TARGETED THERAPY; PRACTICE GUIDELINES AS TOPIC; PYRIDINES; REPUBLIC OF KOREA;

EID: 84855297694     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333277     Document Type: Article

References (31)

1. Park JW: Practice guideline for diagnosis and treatment of hepatocellular carcinoma (in Korean). Korean J Hepatol 2004;10:88-98.
2. Korean Liver Cancer Study Group and National Cancer Center, Korea: Practice guidelines for management of hepatocellular carcinoma 2009 (in Korean). Korean J Hepatol 2009;15:391-423.
3. Camma C, Schepis F, Orlando A, et al: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47-54. (Pubitemid 34680374)
4. Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739. (Pubitemid 34607087)
5. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171. (Pubitemid 34454013)
6. Lee HS, Kim KM, Yoon JH, et al: Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 2002;20:4459-4465. (Pubitemid 35334758)
7. Yamakado K, Nakatsuka A, Takaki H, et al: Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 2008;247:260-266.
8. Lee HS, Kim JS, Choi IJ, et al: The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study. Cancer 1997;79:2087-2094. (Pubitemid 27227372)
9. Chung JW, Park JH, Han JK, et al: Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 1995;165:315-321.
10. Luo J, Guo RP, Lai EC, et al: Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011;18:413-420.
11. Shim SJ, Seong J, Han KH, et al: Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 2005;25:1189-1196. (Pubitemid 41782564)
12. You CR, Jang JW, Kang SH, et al: Efficacy of transarterial chemolipiodolization with or without 3-dimensional conformal radiotherapy for huge HCC with portal vein tumor thrombosis (in Korean). Korean J Hepatol 2007;13:378-386.
13. Mazzaferro V, Regalia E, Doci R, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699. (Pubitemid 26079803)
14. Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(suppl 1):20-37.
15. Hwang S, Lee SG, Joh JW, et al: Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005;11:1265-1272. (Pubitemid 41511942)
16. Lee SG, Hwang S, Moon DB, et al: Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008;14:935-945. (Pubitemid 352003892)
17. Yao FY, Ferrell L, Bass NM, et al: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-1403. (Pubitemid 32496976)
18. Mazzaferro V, Llovet JM, Miceli R, et al: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
19. Yao FY, Kerlan RK, Hirose R, et al: Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48:819-827.
20. Yao FY, Hirose R, LaBerge JM, et al: A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005;11:1505-1514. (Pubitemid 43072626)
21. Jang JW, You CR, Kim CW, et al: Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2010;31:415-423.
22. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
23. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
24. Zhu AX, Clark JW: Commentary: sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis - evidence and controversy. Oncologist 2009;14:67-69.
25. Casanovas O, Hicklin DJ, Bergers G, et al: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309. (Pubitemid 41443415)
26. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
27. Dempke WC, Heinemann V: Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 2009;45:1117-1128.
28. Wang B, Xu H, Gao ZQ, et al: Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008;49:523-529.
29. Meng MB, Cui YL, Lu Y, et al: Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2009;92:184-194.
30. Yamada K, Izaki K, Sugimoto K, et al: Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;57:113-119. (Pubitemid 36959746)
31. Kim DY, Park W, Lim DH, et al: Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005;103:2419-2426. (Pubitemid 40686589)